Effect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model

References

• Nik Hazlina NH, Norhayati MN, Shaiful Bahari I, et al. Worldwide prevalence, risk factors and psychological impact of infertility among women: a systematic review and meta-analysis. BMJ Open. 2022;12(3):e057132.
   PubMed Web of Science ®Google Scholar
• Walker MH, Tobler KJ. Female infertility. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. [Updated 2022 May 26]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556033/
   Google Scholar
• Naredi N, Talwar P, Sandeep K. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: current status. Med J Armed Forces India. 2014;70(1):58–63.
   PubMedGoogle Scholar
• Nastri CO, Ferriani RA, Rocha IA, et al. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet. 2010;27(2-3):121–128.
   PubMed Web of Science ®Google Scholar
• Carizza C, Abdelmassih V, Abdelmassih S, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online. 2008;17(6):751–755.
   PubMed Web of Science ®Google Scholar
• Seow KM, Lin YH, Bai CH, et al. Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial. Reprod Biomed Online. 2013;26(6):562–568.
   PubMed Web of Science ®Google Scholar
• Knoepfelmacher M, Danilovic DL, Rosa Nasser RH, et al. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertil Steril. 2006;86:15–18.
   Web of Science ®Google Scholar
• Zamani A, Qu Z. Serotonin activates angiogenic phosphorylation signaling in human endothelial cells. FEBS Lett. 2012;586(16):2360–2365.
   PubMed Web of Science ®Google Scholar
• Zaidise I, Friedman M, Limdembaum ES, et al. Serotonin and the ovarian hyperstimulation syndrome. Eur J Obstet Gynecol. 1983. Epub 1986 Apl.
   Web of Science ®Google Scholar
• Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome—views and ideas. Hum Reprod. 1997;12(6):1129–1137.
   PubMed Web of Science ®Google Scholar
• Ye JH, PONNUDURAI R, Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev. 2001;7(2):199–213. PMID: 11474424; PMCID: PMC6741689.
   PubMedGoogle Scholar
• Saylan A, Arioz DT, Koken T, et al. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand. 2010;89(5):692–699.
   PubMed Web of Science ®Google Scholar
• Tong XM, Zhang SY, Song T, et al. Effects of gonadotropinreleasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. Chin Med J (Engl). 2008;121:2434–2439.
   PubMed Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147(11):5400–5411.
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Ohba T, Tanaka N, et al. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats. Endocr J. 2003;50(5):515–525.
   PubMed Web of Science ®Google Scholar
• Gómez R, Soares SR, Busso C, et al. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28(6):448–457.
   PubMed Web of Science ®Google Scholar
• Lindenbaum ES, Bar Sela P, Itzkovitz J, et al. Ovarian hyperstimulation in rats. Eur J Obstet Gynecol Reprod Biol. 1980;11(1):57–67.
   PubMed Web of Science ®Google Scholar
• Şanlı C, Atılgan R, Kuloğlu T, et al. Transient receptor potential melastatin 2 ion channel activity in ovarian hyperstimulation syndrome physiopathology. Turk J Med Sci. 2021;51(2):787–795. PMID: 33237659; PMCID: PMC8203159.
   PubMed Web of Science ®Google Scholar
• Motavallian-Naeini A, Minaiyan M, Rabbani M, et al. Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat. Excli J. 2012;11:30–44. PMID: 27350767; PMCID: PMC4919924.
   PubMed Web of Science ®Google Scholar
• Ujioka T, Matsuura K, Kawano T, et al. Role of progesteronein capillary permeability in hyperstimulated rats. Hum Reprod. 1997;12(8):1629–1634.
   PubMed Web of Science ®Google Scholar
• Namavar Jahromi B, Parsanezhad ME, Shomali Z, et al. Ovarian hyperstimulation syndrome: a narrative revi ew of its pathophysiology, risk factors, prevention, classification, and management. Iran J Med Sci. 2018;43(3):248–260. MayPMID: 29892142; PMCID: PMC5993897.
   PubMed Web of Science ®Google Scholar
• Ohba T, Ujioka T, Ishikawa K, et al. Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication. Mol Cell Endocrinol. 2003;202(1-2):47–52.
   PubMed Web of Science ®Google Scholar
• Ujioka T, Matsuura K, Tanaka N, et al. Involvement ofovariankinin-kallikrein system in the pathophysiology of ovarianhyperstimulation syndrome: studies in a rat model. Hum Reprod. 1998;13(11):3009–3015.
   PubMedGoogle Scholar
• Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94(2):389–400. Epub 2010 Apr 22. PMID: 20416867.
   PubMed Web of Science ®Google Scholar
• Engin-Ustun Y, Yılmaz S, Timur H, et al. Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model. Gynecol Endocrinol. 2013;29(9):851–854. Epub 2013 Jul 17. PMID: 23862585.
   PubMed Web of Science ®Google Scholar
• Elia EM, Quintana R, Carrere C, et al. Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study. J Ovarian Res. 2013;6(1):62. PMID: 24011132; PMCID: PMC3851870.
   PubMedGoogle Scholar
• Feng X, Cheng Q, Meng Q, et al. Effects of ondansetron and [6]-gingerol on pica and gut microbiota in rats treated with cisplatin. Drug Des Devel Ther. 2019;13:2633–2641. PMID: 31534312; PMCID: PMC6682320.
   PubMed Web of Science ®Google Scholar
• Atilgan R, Pala Ş, Yavuzkır Ş, et al. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model? J Obstet Gynaecol. 2019;39(5):687–694.
   PubMedGoogle Scholar